Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

Más betegség

• End-stage heart failure due to causes other than ischemic or non-ischemic cardiomyopathy (e.g., valvular, hypertrophic or infiltrative cardiomyopathies).
• Tissue physiology or other factors that, in the opinion of the Cardiac Surgeons, make the patient at unacceptably high risk for adverse outcomes.
• Non-compliance with current treatments, including failure to follow prescribed therapies, such as medications, clinic visits, diagnostic testing and behavioral contracts
• Known allergies to niacin, nicotinamide or warfarin

Laborértékek

• Disease that disqualifies from consideration for LVAD implantation by the University of Washington program:
  • Cirrhosis as evidenced by liver biopsy
  • Irreversible, severe renal disease (estimated glomerular filtration rate (eGFR) \<30) or on chronic dialysis
  • Untreated thyroid disease (hyper- or hypo-thyroidism)
  • Severe complications of diabetes, such as diabetes-related amputation, severe retinopathy, peripheral neuropathy or diabetic renal disease (eGFR \<30)

Egyéb

• Active use/abuse of illicit substances
• Lack of adequate caregiver support to help patient manage LVAD
• Inability to perform Study visits or procedures
• Unwillingness/inability to provide informed consent.
• Participants considered by the attending cardiologist and/or the investigator to be unsuitable for the study

• End-stage heart failure due to ischemic or non-ischemic cardiomyopathy
  • If implanted for destination therapy indication, must have New Your Heart Association (NYHA) Class IV Heart Failure AND left ventricular ejection fraction (LVEF) \<25% OR maximum minute consumption of oxygen (VO2) \<14 OR on requirement for continuous intravenous inotropes
• Meet clinical and socioeconomic screening criteria for elective LVAD implantation by the University of Washington Mechanical Circulatory Support Program
• Scheduled (or soon to be scheduled) for elective LVAD implantation
• Age \>18 years